Autologous OC-L Vaccine and Ovarian Cancer

Summary

This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Timeline

Start

2015-05

Primary completion

2018-05-30

Completion

2018-05-30

Drugs

Indications